Flamel Technologies Report issue

For profit Phase 2 Phase 3
Founded: Vennisieux France (1990)
Status: Acquired by Avadel Pharmaceuticals (2017)

Organization Overview

First Clinical Trial
2010
NCT01010646
First Marketed Drug
2016
methylene blue (proveblue)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Flame Biosciences | Flamel Ireland Limited | FLAMEL IRELAND LTD